等待内容更新

【消胆胺药品名称】
通用名：考来烯胺散
英文名：Cholestyramine Powder

【消胆胺成份】
消胆胺主要成分及其化学名称为：聚苯乙烯季胺型强碱性阴离子交换树脂的氯化物。

【消胆胺性状】
消胆胺为白色至类白色粉末。

【消胆胺药理毒理】
消胆胺在小肠内与胆酸结合，形成不溶性化合物阻止其重吸收，而随粪便排泄。消胆胺与胆汁酸在小肠中结合后导致胆汁酸在肝内合成的增加，由于胆汁酸的合成是以胆固醇为底物，使得肝内胆固醇减少，从而使肝脏低密度脂蛋白受体活性增加而去除血浆中低密度脂蛋白。消胆胺增加肝脏极低密度脂蛋白的合成，从而增加血浆中甘油三酯的浓度，特别是高甘油三酯血症者。消胆胺降低血清中的胆酸，可缓解因胆酸过多而沉积于皮肤所致的瘙痒。
消胆胺增加大鼠在服用强致癌物时的小肠肿瘤的发生率。

【消胆胺药代动力学】
消胆胺不从胃肠道吸收。用药后1-2周，血浆胆固醇浓度开始降低，可持续降低1年以上。部分病人在治疗过程中，血清胆固醇浓度开始降低，后又恢复至或超过基础水平。用药后1-3周，因胆汁淤滞所致的瘙痒得到缓解。停药后2-4周血浆胆固醇浓度恢复至基础水平。停药1-2周后，再次出现因胆汁淤滞所致的瘙痒。

【消胆胺适应症】
消胆胺可用于Ⅱa型高脂血症，高胆固醇血症。消胆胺降低血浆总胆固醇和低密度脂蛋白浓度，对血清甘油三酯浓度无影响或使之轻度升高，因此，对单纯甘油三酯升高者无效。消胆胺还可用于胆管不完全阻塞所致的瘙痒。

【消胆胺规格】
5g：4g（考来烯胺干燥品）

【消胆胺用法用量】
成人剂量口服：维持量，每日2~24g（无水考来烯胺，1/2～6袋），用于止痒为16g（无水考来烯胺，4袋），分3次于饭前服或与饮料拌匀服用。
小儿剂量口服：用于降血脂，初始剂量，每日4g（无水考来烯胺，1袋），分2次服用，维持剂量为每日2~24g（无水考来烯胺，1/2～6袋），分2次或多次服用。

【消胆胺不良反应】
多发生于服用大剂量及超过60岁的病人。有报道，长期服用消胆胺偶尔可致骨质疏松。
1．较常见的有：
（1）便秘，通常程度较轻，短暂性，但可能很严重，可引起肠梗阻；
（2）烧心感；（3）消化不良；（4）恶心、呕吐；（5）胃痛。
2．较少见的有：
（1）胆石症；（2）胰腺炎；（3）胃肠出血或胃溃疡；（4）脂肪泻或吸收不良综合征；
（5）嗳气；（6）肿胀；（7）眩晕；（8）头痛。

【消胆胺禁忌】
1．对考来烯胺过敏的患者禁用。
2．胆道完全闭塞的患者禁用。

【消胆胺注意事项】
1．便秘患者慎用。
2．合并甲状腺功能减退症、糖尿病、肾病、血蛋白异常或阻塞性肝病患者，服用消胆胺同时应对上述疾病进行治疗。
3．长期服用应注意出血倾向；年轻患者用较大剂量易产生高氯性酸中毒。
4．长期服用消胆胺同时应补充脂溶性维生素（以肠道外给药途径为佳）。
5．消胆胺增加大鼠在服用强致癌物质时的小肠肿瘤发生率。
6．对孕妇的影响还缺乏人体研究。消胆胺口服后几乎完全不被吸收，但可能影响孕妇对维生素及其他营养物质的吸收，对胎儿产生不良作用。
7．对哺乳婴儿的影响尚缺乏人体研究。消胆胺口服后几乎完全不被吸收，但可能影响乳母对维生素及其他营养物质的吸收，对乳儿产生不利影响。

【消胆胺孕妇及哺乳期妇女用药】
消胆胺对孕妇及哺乳期妇女的影响还缺乏人体研究，消胆胺口服后几乎完全不被吸收，但可能影响孕妇及哺乳期妇女对维生素及其它营养物质的吸收，对胎儿和乳儿产生不利影响。

【消胆胺儿童用药】
由于考来烯胺是离子交换树脂的氯化物形式，因此长期使用后可造成血氯过多酸中毒，特别是对儿童。有报道患高氯血的儿童服用消胆胺可导致血叶酸浓度下降，建议在治疗期间补充叶酸。

 
【消胆胺药物相互作用】
考来烯胺可延缓或降低其它与之同服的药物吸收，特别是酸性药物，减少了肝肠循环。这些药物包括：噻嗪类利尿药、普萘洛尔、地高辛和其它生物碱类药物、洛哌丁胺、保泰松、巴比妥酸盐类、雌激素、孕激素、甲状腺激素、华法林及某些抗生素，为避免药物相互作用的发生，可在消胆胺服用前1小时或服用后4-6小时再服用其它药物。

 
【消胆胺贮藏】
避光、密封、在干燥处保存。

Questran Description

Questran ® (Cholestyramine for Oral Suspension USP), the chloride salt of a basic anion exchange resin, a cholesterol lowering agent, is intended for oral administration. Cholestyramine resin is quite hydrophilic, but insoluble in water. The cholestyramine resin in Questran is not absorbed from the digestive tract. Four grams of anhydrous cholestyramine resin is contained in 9 grams of Questran powder. Four grams of anhydrous cholestyramine resin is contained in 5 grams of Questran LIGHT. It is represented by the following structural formula:

 

Cholesterol is probably the sole precursor of bile acids. During normal digestion, bile acids are secreted into the intestines. A major portion of the bile acids is absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation. Only very small amounts of bile acids are found in normal serum.

Questran resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces. This results in a partial removal of bile acids from the enterohepatic circulation by preventing their absorption.

The increased fecal loss of bile acids due to Questran administration leads to an increased oxidation of cholesterol to bile acids, a decrease in beta lipoprotein or low density lipoprotein plasma levels and a decrease in serum cholesterol levels. Although in man, Questran produces an increase in hepatic synthesis of cholesterol, plasma cholesterol levels fall.

In patients with partial biliary obstruction, the reduction of serum bile acid levels by Questran reduces excess bile acids deposited in the dermal tissue with resultant decrease in pruritus.

Questran (Cholestyramine for Oral Suspension USP) contains the following inactive ingredients: acacia, citric acid, D&C Yellow No. 10, FD&C Yellow No. 6, flavor (natural and artificial Orange), polysorbate 80, propylene glycol alginate and sucrose. Questran LIGHT (Cholestyramine for Oral Suspension USP, Light) contains the following inactive ingredients: aspartame, citric acid, colloidal silicon dioxide, D&C Yellow No. 10, FD&C Red No. 40, flavor (natural and artificial Orange), maltodextrin, propylene glycol alginate and xanthan gum.

Questran - Clinical Pharmacology

Cholesterol is probably the sole precursor of bile acids. During normal digestion, bile acids are secreted into the intestines. A major portion of the bile acids is absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation. Only very small amounts of bile acids are found in normal serum.

 

Cholestyramine resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces. This results in a partial removal of bile acids from the enterohepatic circulation by preventing their absorption.

The increased fecal loss of bile acids due to Cholestyramine administration leads to an increased oxidation of cholesterol to bile acids, a decrease in beta lipoprotein or low density lipoprotein plasma levels and a decrease in serum cholesterol levels. Although in man, Cholestyramine produces an increase in hepatic synthesis of cholesterol, plasma cholesterol levels fall.

In patients with partial biliary obstruction, the reduction of serum bile acid levels by Cholestyramine reduces excess bile acids deposited in the dermal tissue with resultant decrease in pruritus.

Indications and Usage for Questran

1) Questran (Cholestyramine for Oral Suspension USP), is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Questran may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern.

Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight.

Prior to initiating therapy with Questran, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation:

LDL-C = Total cholesterol – [(TG/5) + HDL-C]

For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Questran may not be indicated.

Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Questran therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Questran or adding other lipid-lowering agents in combination with Questran should be considered.

Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below.

*Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease).
**Other risk factors for coronary heart disease (CHD) include: age (males ≥45 years; females ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (<0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (≥1.6 mmol/L).
			LDL-Cholesterol mg/dL (mmol/L)
Definite Atherosclerotic Disease*	Two or More Other Risk Factors**	Initiation Level	Goal
NO	NO	≥190 (≥4.9)	<160 (<4.1)
NO	YES	≥160 (≥4.1)	<130 (<3.4)
YES	YES or NO	≥130 (≥3.4)	≤100 (≤2.6)

1) Questran monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression3 of coronary atherosclerosis.

2) Questran is indicated for the relief of pruritus associated with partial biliary obstruction. Questran for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease.

Contraindications

Questran is contraindicated in patients with complete biliary obstruction where bile is not secreted into the intestine and in those individuals who have shown hypersensitivity to any of its components.

Warnings

PHENYLKETONURICS: CHOLESTYRAMINE for ORAL SUSPENSION USP, LIGHT CONTAINS 14.0 mg PHENYLALANINE PER 5 GRAM DOSE.

PrecautionsGeneral

Chronic use of Questran may be associated with increased bleeding tendency due to hypoprothrombinemia associated with Vitamin K deficiency. This will usually respond promptly to parenteral Vitamin K1 and recurrences can be prevented by oral administration of Vitamin K1. Reduction of serum or red cell folate has been reported over long term administration of Questran. Supplementation with folic acid should be considered in these cases.

There is a possibility that prolonged use of Questran, since it is a chloride form of anion exchange resin, may produce hyperchloremic acidosis. This would especially be true in younger and smaller patients where the relative dosage may be higher. Caution should also be exercised in patients with renal insufficiency or volume depletion, and in patients receiving concomitant spironolactone.

Questran may produce or worsen pre-existing constipation. The dosage should be increased gradually in patients to minimize the risk of developing fecal impaction. In patients with pre-existing constipation, the starting dose should be 1 packet or 1 scoop once daily for 5–7 days, increasing to twice daily with monitoring of constipation and of serum lipoproteins, at least twice, 4–6 weeks apart. Increased fluid intake and fiber intake should be encouraged to alleviate constipation and a stool softener may occasionally be indicated. If the initial dose is well tolerated, the dose may be increased as needed by one dose/day (at monthly intervals) with periodic monitoring of serum lipoproteins. If constipation worsens or the desired therapeutic response is not achieved at one to six doses/day, combination therapy or alternate therapy should be considered. Particular effort should be made to avoid constipation in patients with symptomatic coronary artery disease. Constipation associated with Questran may aggravate hemorrhoids.

Information for Patients

Inform your physician if you are pregnant or plan to become pregnant or are breastfeeding. Drink plenty of fluids and mix each 9 gram dose of Questran Powder in at least 2 to 6 ounces of fluid. Mix each 5 gram dose of Questran LIGHT in at least 2 to 6 ounces of fluid before taking. Sipping or holding the resin suspension in the mouth for prolonged periods may lead to changes in the surface of the teeth resulting in discoloration, erosion of enamel or decay; good oral hygiene should be maintained.

Laboratory Tests

Serum cholesterol levels should be determined frequently during the first few months of therapy and periodically thereafter. Serum triglyceride levels should be measured periodically to detect whether significant changes have occurred.

The LRC-CPPT showed a dose-related increase in serum triglycerides of 10.7%–17.1% in the cholestyramine-treated group, compared with an increase of 7.9%–11.7% in the placebo group. Based on the mean values and adjusting for the placebo group, the cholestyramine-treated group showed an increase of 5% over pre-entry levels the first year of the study and an increase of 4.3% the seventh year.

Drug Interactions

Questran (Cholestyramine for Oral Suspension USP) may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. Interference with the absorption of oral phosphate supplements has been observed with another positively-charged bile acid seQuestrant. Questran may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation. The discontinuance of Questran could pose a hazard to health if a potentially toxic drug such as digitalis has been titrated to a maintenance level while the patient was taking Questran.

Because cholestyramine binds bile acids, Questran may interfere with normal fat digestion and absorption and thus may prevent absorption of fat-soluble vitamins such as A, D, E and K. When Questran is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered.

 

SINCE Questran MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST ONE HOUR BEFORE OR 4 TO 6 HOURS AFTER Questran (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.

Carcinogenesis and Mutagenesis and Impairment of Fertility

In studies conducted in rats in which cholestyramine resin was used as a tool to investigate the role of various intestinal factors, such as fat, bile salts and microbial flora, in the development of intestinal tumors induced by potent carcinogens, the incidence of such tumors was observed to be greater in cholestyramine resin-treated rats than in control rats.

The relevance of this laboratory observation from studies in rats to the clinical use of Questran is not known. In the LRC-CPPT study referred to above, the total incidence of fatal and nonfatal neoplasms was similar in both treatment groups. When the many different categories of tumors are examined, various alimentary system cancers were somewhat more prevalent in the cholestyramine group. The small numbers and the multiple categories prevent conclusions from being drawn. However, in view of the fact that cholestyramine resin is confined to the GI tract and not absorbed, and in light of the animal experiments referred to above, a six-year post-trial follow-up of the LRC-CPPT 5 patient population has been completed (a total of 13.4 years of in-trial plus post-trial follow-up) and revealed no significant difference in the incidence of cause-specific mortality or cancer morbidity between cholestyramine and placebo treated patients.

Pregnancy

Pregnancy Category C

There are no adequate and well controlled studies in pregnant women. The use of Questran in pregnancy or lactation or by women of childbearing age requires that the potential benefits of drug therapy be weighed against the possible hazards to the mother and child. Questran is not absorbed systemically, however, it is known to interfere with absorption of fat-soluble vitamins; accordingly, regular prenatal supplementation may not be adequate (see PRECAUTIONS: Drug Interactions).

Nursing Mothers

Caution should be exercised when Questran is administered to a nursing mother. The possible lack of proper vitamin absorption described in the “Pregnancy” section

Pediatric Use

Although an optimal dosage schedule has not been established, standard texts (6,7) list a usual pediatric dose of 240 mg/kg/day of anhydrous cholestyramine resin in two to three divided doses, normally not to exceed 8 gm/day with dose titration based on response and tolerance.

In calculating pediatric dosages, 44.4 mg of anhydrous choleystramine resin are contained in 100 mg of Questran powder and 80 mg of anhydrous cholestyramine resin are contained in 100 mg of Questran LIGHT.

The effects of long-term administration, as well as its effect in maintaining lowered cholesterol levels in pediatric patients, are unknown. (Also see ADVERSE REACTIONS.)

Adverse Reactions

The most common adverse reaction is constipation. When used as a cholesterol-lowering agent predisposing factors for most complaints of constipation are high dose and increased age (more than 60 years old). Most instances of constipation are mild, transient, and controlled with conventional therapy. Some patients require a temporary decrease in dosage or discontinuation of therapy.

Less Frequent Adverse Reactions: Abdominal discomfort and/or pain, flatulence, nausea, vomiting, diarrhea, eructation, anorexia, and steatorrhea, bleeding tendencies due to hypoprothrombinemia (Vitamin K deficiency) as well as Vitamin A (one case of night blindness reported) and D deficiencies, hyperchloremic acidosis in children, osteoporosis, rash and irritation of the skin, tongue and perianal area. Rare reports of intestinal obstruction, including two deaths, have been reported in pediatric patients.

Occasional calcified material has been observed in the biliary tree, including calcification of the gallbladder, in patients to whom Questran has been given. However, this may be a manifestation of the liver disease and not drug related.

One patient experienced biliary colic on each of three occasions on which he took Questran. One patient diagnosed as acute abdominal symptom complex was found to have a “pasty mass” in the transverse colon on x-ray.

Other events (not necessarily drug related) reported in patients taking Questran include:

 

Gastrointestinal—GI-rectal bleeding, black stools, hemorrhoidal bleeding, bleeding from known duodenal ulcer, dysphagia, hiccups, ulcer attack, sour taste, pancreatitis, rectal pain, diverticulitis.

Laboratory test changes—Liver function abnormalities.

Hematologic—Prolonged prothrombin time, ecchymosis, anemia

Hypersensitivity—Urticaria, asthma, wheezing, shortness of breath.

Musculoskeletal—Backache, muscle and joint pains, arthritis.

Neurologic—Headache, anxiety, vertigo, dizziness, fatigue, tinnitus, syncope, drowsiness, femoral nerve pain, paresthesia.

Eye—Uveitis.

Renal—Hematuria, dysuria, burnt odor to urine, diuresis.

Miscellaneous—Weight loss, weight gain, increased libido, swollen glands, edema, dental bleeding, dental caries, erosion of tooth enamel, tooth discoloration.

 

Overdosage

Overdosage with Questran has been reported in a patient taking 150% of the maximum recommended daily dosage for a period of several weeks. No ill effects were reported. Should an overdosage occur, the chief potential harm would be obstruction of the gastrointestinal tract. The location of such potential obstruction, the degree of obstruction, and the presence or absence of normal gut motility would determine treatment.

Questran Dosage and Administration

The recommended starting adult dose for all Questran powdered products (Questran Powder and Questran Light) is one packet or one level scoopful once or twice a day. The recommended maintenance dose for all Questran powdered products is 2 to 4 packets or scoopfuls daily (8-16 grams anhydrous cholestyramine resin) divided into two doses. Four grams of anhydrous cholestyramine resin is contained in each measured dose of Questran as follows:

 

Questran Powder	9 grams
Questran Light	5 grams

It is recommended that increases in dose be gradual with periodic assessment of lipid/lipoprotein levels at intervals of not less than 4 weeks. The maximum recommended daily dose is six packets or scoopfuls of Questran (24 grams of anhydrous cholestyramine resin). The suggested time of administration is at mealtime but may be modified to avoid interference with absorption of other medications. Although the recommended dosing schedule is twice daily, Questran may be administered in 1–6 doses per day.

Questran should not be taken in its dry form. Always mix Questran with water or other fluids before ingesting. See Preparation Instructions.

Concomitant Therapy

Preliminary evidence suggests that the lipid-lowering effects of Questran on total and LDL-cholesterol are enhanced when combined with a HMG-CoA reductase inhibitor, e.g., pravastatin, lovastatin, simvastatin, and fluvastatin. Additive effects on LDL-cholesterol are also seen with combined nicotinic acid/Questran therapy. See the Drug Interactions subsection of the PRECAUTIONS section for recommendations on administering concomitant therapy.

PREPARATION

The color of Questran may vary somewhat from batch to batch but this variation does not affect the performance of the product. Place the contents of one single-dose packet or one level scoopful of Questran in a glass or cup. Add an amount of water or other noncarbonated beverage of your choice depending on the product being used:

Product Formula	Amount of Water or other Non-Carbonated Liquid
Questran Powder	2-6 ounces per dose
Questran LIGHT	2-6 ounces per dose

Stir to a uniform consistency and drink.

Questran may also be mixed with highly fluid soups or pulpy fruits with a high moisture content such as applesauce or crushed pineapple.

How is Questran Supplied

Questran ® Powder (Cholestyramine for Oral Suspension USP) is available in cans containing 378 grams and in cartons of sixty 9 gram packets. Four grams of anhydrous cholestyramine resin are contained in 9 grams of Questran Powder. The 378 g can includes a 15 cc scoop. The scoop is not interchangeable with scoops from other products.

NDC 49884-936-66	Can, 378 g
NDC 49884-936-65	Carton of 60, 9 g packets

Questran ® LIGHT (Cholestyramine for Oral Suspension USP), Light is available in cans containing 210 grams and in cartons of sixty 5 gram packets. Four grams of anhydrous cholestyramine resin are contained in 5 grams of Questran LIGHT. The 210 g can includes a 9 cc scoop. The scoop is not interchangeable with scoops from other products.

NDC 49884-937-67	Can, 210 g
NDC 49884-937-65	Carton of 60, 5 g packets

Storage

Store between 20º-25ºC (68º-77ºF). [See USP Controlled Room Temperature]. Excursions permitted to 15º-30ºC (59º-86ºF).

Clinical Studies

In a large, placebo-controlled, multi-clinic study, LRC-CPPT 1, hypercholesterolemic subjects treated with Questran had mean reductions in total and low-density lipoprotein cholesterol (LDL-C) which exceeded those for diet and placebo treatment by 7.2% and 10.4%, respectively. Over the seven-year study period the Questran group experienced a 19% reduction (relative to the incidence in the placebo group) in the combined rate of coronary heart disease death plus non-fatal myocardial infarction (cumulative incidences of 7% Questran and 8.6% placebo). The subjects included in the study were men aged 35 - 59 with serum cholesterol levels above 265 mg/dL and no previous history of heart disease. It is not clear to what extent these findings can be extrapolated to females and other segments of the hypercholesterolemic population. (See also PRECAUTIONS: Carcinogenesis, Mutagenesis, Impairment of Fertility.)

Two controlled clinical trials have examined the effects of Questran monotherapy upon coronary atherosclerotic lesions using coronary arteriography. In the NHLBI Type II Coronary Intervention Trial 2, 116 patients (80% male) with coronary artery disease (CAD) documented by arteriography were randomized to Questran or placebo for five years of treatment. Final study arteriography revealed progression of coronary artery disease in 49% of placebo patients compared to 32% of the Questran group (p<0.05).

In the St. Thomas Atherosclerosis Regression Study (STARS) 3, 90 hypercholesterolemic men with CAD were randomized to three blinded treatments: usual care, lipid-lowering diet, and lipid-lowering diet plus Questran. After 36 months, follow-up coronary arteriography revealed progression of disease in 46% of usual care patients, 15% of patients on lipid-lowering diet and 12% of those receiving diet plus Questran (p<0.02). The mean absolute width of coronary segments decreased in the usual care group, increased slightly (0.003mm) in the diet group and increased by 0.103mm in the diet plus Questran group (p<0.05). Thus in these randomized controlled clinical trials using coronary arteriography, Questran monotherapy has been demonstrated to slow progression 2,3 and promote regression3 of atherosclerotic lesions in the coronary arteries of patients with coronary artery disease.

The effect of intensive lipid-lowering therapy on coronary atherosclerosis has been assessed by arteriography in hyperlipidemic patients. In these randomized, controlled clinical trials, patients were treated for two to four years by either conventional measures (diet, placebo, or in some cases low dose resin), or intensive combination therapy using diet plus colestipol (an anion exchange resin with a mechanism of action and an effect on serum lipids similar to that of Questran and Questran LIGHT) plus either nicotinic acid or lovastatin. When compared to conventional measures, intensive lipid-lowering combination therapy significantly reduced the frequency of progression and increased the frequency of regression of coronary atherosclerotic lesions in patients with or at risk for coronary artery disease.

REFERENCES

•

The Lipid Research Clinics Coronary Primary Prevention Trial Results: (I) Reduction in Incidence of Coronary Heart Disease; (II) The Relationship of Reduction in Incidence of Coronary Heart Disease to Cholesterol Lowering. JAMA 1984; 251:351-374.

•

Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI type II coronary intervention study. Circulation 1984;69:313-24.

•

Watts, GF, Lewis B, Brunt JNH, Lewis ES, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-69.

•

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994 Mar; 89(3):1333-445.

•

The Lipid Research Clinics Investigators. The Lipid Research Clinics Coronary Primary Prevention Trial: Results of 6 Years of Post-Trial Follow-up. Arch Intern Med 1992; 152:1399-1410.

•

Behrman RE et al (eds): Nelson, Textbook of Pediatrics, ed 15. Philadelphia, PA, WB Saunders Company, 1996.

•

Takemoto CK et al (eds): Pediatric Dosage Handbook, ed 3. Cleveland/Akron, OH, Lexi-Comp, Inc., 1996-1997.

Distributed by:

PAR PHARMACEUTICAL COMPANIES, INC.

Spring Valley, NY 10977

Revised: 05/06

OS466-65-1-02

PRINCIPAL DISPLAY PANEL, 378 GRAM CAN

 

PRINCIPAL DISPLAY PANEL, CARTON 60 PACKETS PER CARTON

 

PRINCIPAL DISPLAY PANEL, 9 GRAM PACKET

 

PRINCIPAL DISPLAY PANEL, 210 GRAM CAN

 

PRINCIPAL DISPLAY PANEL, CARTON 60 PACKETS PER CARTON

 

PRINCIPAL DISPLAY PANEL, 5 GRAM PACKET

 

Questran cholestyramine powder, for suspension

Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:49884-936 Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength CHOLESTYRAMINE (CHOLESTYRAMINE) CHOLESTYRAMINE 4 g  in 9 g

Inactive Ingredients Ingredient Name Strength ACACIA   D&C YELLOW NO. 10   FD&C YELLOW NO. 6   POLYSORBATE 80   PROPYLENE GLYCOL ALGINATE   SUCROSE   ANHYDROUS CITRIC ACID

Product Characteristics Color      Score      Shape   Size   Flavor ORANGE Imprint Code   Contains

Packaging # Item Code Package Description   1 NDC:49884-936-65 60 PACKET in 1 CARTON   1 NDC:49884-936-64 9 g in 1 PACKET   2 NDC:49884-936-66 378 g in 1 CAN

Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA077204 09/15/2005

Questran cholestyramine powder, for suspension

Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:49884-937 Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength CHOLESTYRAMINE (CHOLESTYRAMINE) CHOLESTYRAMINE 4 g  in 5 g

Inactive Ingredients Ingredient Name Strength ACACIA   D&C YELLOW NO. 10   FD&C YELLOW NO. 6   POLYSORBATE 80   PROPYLENE GLYCOL ALGINATE   SUCROSE   ANHYDROUS CITRIC ACID

Product Characteristics Color      Score      Shape   Size   Flavor ORANGE Imprint Code   Contains

Packaging # Item Code Package Description   1 NDC:49884-937-65 60 PACKET in 1 CARTON   1 NDC:49884-937-63 5 g in 1 PACKET   2 NDC:49884-937-67 210 g in 1 CAN

Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA077203 07/24/2003

Labeler - Par Pharmaceutical Inc. (092733690)

Registrant - Par Pharmaceutical Inc. (092733690)

Establishment
Name	Address	ID/FEI	Operations
Par Pharmaceutical Inc.		092733690	MANUFACTURE(49884-936, 49884-937)

Revised: 01/2015